文献速递神经肌肉病

EMBARK试验:delandistrogene moxeparvovec治疗DMD的肌肉定量MRI探索性分析

Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2025-01-01

EMBARK随机对照试验的探索性分析纳入131例DMD患者中的39例接受肌肉QMR成像,评估delandistrogene moxeparvovec对肌肉脂肪分数和T2的影响。

要点

  • 治疗组在52周时多个肌肉的脂肪分数变化优于安慰剂。
  • 治疗组4/5肌肉T2降低,安慰剂组全部肌肉T2升高。

核心结论

  • QMR指标一致支持delandistrogene moxeparvovec治疗获益,表现为脂肪积累减少和T2改善。

研究设计与样本

  • 3期双盲安慰剂对照多中心随机临床试验,共131例患者随机,125例接受治疗(delandistrogene moxeparvovec组63例,安慰剂组62例)。
  • 本探索性分析聚焦于接受肌肉QMR成像的39例男性患者(治疗组19例,安慰剂组20例)。

主要发现

  • MRS脂肪分数组间最小二乘均值差异范围:比目鱼肌-1.01(95%CI -2.79至0.77),股外侧肌-0.71(95%CI -3.21至1.80)。
  • MRI脂肪分数组间差异范围:股外侧肌-3.09(95%CI -7.62至1.45),腘绳肌-0.44(95%CI -4.01至3.12)。
  • T2组内最小二乘均值变化:治疗组比目鱼肌-1.06(95%CI -2.10至-0.02),股二头肌0.17(95%CI -1.76至2.10);安慰剂组比目鱼肌1.12(95%CI 0.08至2.16),股四头肌2.94(95%CI 0.84至5.03)。

临床怎么用

  • QMR成像可作为评估DMD疾病进展和治疗反应的探索性生物标志物。
  • delandistrogene moxeparvovec可能稳定或减缓肌肉病理进展,支持其疾病修饰作用。

局限性

  • 本分析为探索性分析,仅纳入39例接受QMR成像的患者,样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Delandistrogene moxeparvovec is a recombinant adeno-associated virus rhesus isolate serotype 74 vector-based gene transfer therapy for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed pathogenic variant of the DMD gene. In a subset of patients in the EMBARK (A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec [SRP-9001] in Participants With DMD) randomized clinical trial, changes in muscle health and pathology were assessed to evaluate the therapeutic impact of the treatment on disease progression. OBJECTIVE: To determine the effect of delandistrogene moxeparvovec on muscle quantitative magnetic resonance (QMR) measures of disease progression in patients in the EMBARK trial. DESIGN, SETTING, AND PARTICIPANTS: This was a phase 3, double-blind, placebo-controlled (October 2021-September 2023; week 52 cutoff date: September 13, 2023), multicenter randomized clinical trial that included 131 patients. Patients were randomized, and 125 were treated with either delandistrogene moxeparvovec (n = 63) or placebo (n = 62). The current study focused on a subset of patients who underwent muscle QMR imaging. INTERVENTION: Single-administration intravenous delandistrogene moxeparvovec (1.33 × 1014 vector genome/kg) or placebo. MAIN OUTCOMES AND MEASURES: Change from baseline to week 52 in muscle MR was a prespecified exploratory end point. Proton MR spectroscopy (MRS) and 8-point Dixon MR imaging (MRI) measured muscle fat fraction (FF); multislice spin echo MRI measured transverse relaxation time (T2). MRS FF was measured in the soleus and vastus lateralis. MRI FF and T2 were measured in 5 leg muscle locations important for ambulation. A post hoc global statistical test combining all muscles and modalities assessed overall treatment effect. RESULTS: In this exploratory EMBARK analysis, 39 male participants (delandistrogene moxeparvovec, n = 19; placebo, n = 20; mean [SD] age, 6.10 [1.04] years; mean [SD] baseline North Star Ambulatory Assessment total score, 22.99 [3.71] points) underwent muscle MRI. Treated patients showed less disease progression vs placebo on MR measures. Across muscles and modalities, magnitudes of FF change favored delandistrogene moxeparvovec; between-group differences in least-squares mean change ranged from -1.01 (95% CI, -2.79 to 0.77; soleus) to -0.71 (95% CI, -3.21 to 1.80; vastus lateralis) for MRS FF and -3.09 (95% CI, -7.62 to 1.45; vastus lateralis) to -0.44 (95% CI, -4.01 to 3.12; hamstrings) for MRI FF. T2 reductions (improvements; 4 of 5 muscles) were observed in treated patients vs increases (worsening; all muscles) in placebo patients; within-group differences in least-squares mean change ranged from -1.06 (95% CI, -2.10 to -0.02; soleus) to 0.17 (95% CI, -1.76 to 2.10; biceps femoris) in the delandistrogene moxeparvovec group and from 1.12 (95% CI, 0.08-2.16; soleus) to 2.94 (95% CI, 0.84-5.03; quadriceps) in the placebo group. The global statistical test supported treatment benefit (P = .03). CONCLUSIONS AND RELEVANCE: Results reveal that QMR outcomes consistently favored delandistrogene moxeparvovec across muscle groups, with treatment leading to decreased fat accumulation and improved T2 vs placebo over 52 weeks. Consistent with treatment effects on functional outcomes observed in the EMBARK trial, these results suggest stabilization or less progression of muscle pathology with delandistrogene moxeparvovec-adding to the totality of evidence supporting disease stabilization or slowing of disease progression with delandistrogene moxeparvovec. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05096221.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Vandenborne K, Walter GA, Straub V, et al. Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 40354061. doi:10.1001/jamaneurol.2025.0992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。